Sort
48,018 grants matching “immunotherapy”
Cancer immunotherapy
$1,503,964Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
NOVEL IMMUNE BASED THERAPIES FOR MULTIPLE MYELOMA
$1,503,053Dana-Farber Cancer Institute · P01 · FY2001 · CA
American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)
$1,502,614Terry B Gernsheimer · University Of Washington · U01 · FY2017 · HL
MIAMI ADULT AIDS CLINICAL TRIALS GROUP, AACTG
$1,501,740University Of Miami School Of Medicine · U01 · FY2003 · AI
Cell Production Core Facility
$1,501,220Hyunmi Halas · Division Of Basic Sciences - Nci · ZIC · FY2022 · CA
Surgery Branch Cell Prep Core
$1,501,220Hyunmi Halas · Division Of Basic Sciences - Nci · ZIC · FY2022 · CA
Dendritic Cell-Based Immunotherapy for HIV Infection
$1,500,000University Of Pittsburgh At Pittsburgh · P01 · FY2005 · AI
Stanford University Cancer Center
$1,500,000Irving Lerner Weissman · Stanford University · P30 · FY2007 · CA
Towards a preventive cancer vaccine for children with constitutional mismatch repair deficiency
$1,500,000Brad H. Pollock · Public Health Institute · UG1 · FY2022 · CA
Miami Center for AIDS Research
$1,500,000Rana Chakraborty · University Of Miami School Of Medicine · P30 · FY2025 · AI
Metabolomic and Genetic Factors Decoupling Immune Checkpoint Inhibitor Tumor Efficacy and Cardiovascular Toxicity
$1,499,996Nicolas Palaskas · University Of Tx Md Anderson Can Ctr · U01 · FY2025 · FD
SBIR TOPIC 342 - Direct to Phase II: Melanoma Early Detection RCT With Smartphones, Cognitive Computing & Family Social Support
$1,499,971Praduman Jain · Vignet, Inc. · N44 · FY2017 · CA
Monitoring Anticancer Immune Response Non-Invasively with [18F]F-AraG PET Imaging
$1,499,971Shahriar Yaghoubi · Cellsight Technologies, Inc. · N44 · FY2013 · CA
Clinical and Mechanistic Investigations of Salivary Gland Dysfunction
$1,499,358Blake Warner · National Institute Of Dental & Craniofacial Research · ZIA · FY2021 · DE
TAS::75 0849 - TOPIC 255 PHASE II, CGMP MANUFACTURE OF A NOVEL CEA EXPRESSING A
$1,499,001Frank R. Jones · Etubics Corporation · N44 · FY2011 · CA
ETIB Clinical Research Core
$1,498,841Ronald Gress · Division Of Basic Sciences - Nci · ZID · FY2021 · CA
SBIR Topic 354: A Novel Predictive Test for Response to Combination Immunotherapies for Patients with non-small cell lung cancer (NSCLC)
$1,498,027Greg Bertenshaw · Biomarker Strategies, Llc · N44 · FY2019 · CA
RNA TRASFECTED DENDRITIC CELLS FOR CANCER IMMUNOTHERAPY
$1,497,862Duke University · P01 · FY2002 · CA
Interrupting Cellular Crosstalk in the Immunosuppressive Microenvironment of Pancreas Cancer
$1,497,616Howard C Crawford · University Of Michigan At Ann Arbor · U01 · FY2017 · CA
SYNERGISTIC MULTIMODALITY ANTIBODY THERAPY
$1,497,565University Of California Davis · P01 · FY2000 · CA
Immunological Strategies to Modulate SIV Rebound Following ART Interruption
$1,497,359Michael R Betts · University Of Pennsylvania · P01 · FY2021 · AI
Specialized Center of Research Excellence on Sex Differences in Autoimmunity
$1,496,169Paul Joseph Utz · Stanford University · U54 · FY2025 · AR
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma
$1,495,060Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Targeting the Chemokine System to Sensitize Tumors to Immunotherapy
$1,494,670Pawel Kalinski · Roswell Park Cancer Institute Corp · P01 · FY2024 · CA
Novel Targets for Immunotherapy
$1,493,975Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2021 · CA